TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03645746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: REGN5069 will be administered by IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: REGN5069 will be administered by IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: REGN5069 will be administered by IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: REGN5069 will be administered by IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: REGN5069 will be administered by IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: REGN5069 will be administered by IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: REGN5069 will be administered by IV infusion or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN5069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN5069
Study: NCT03922737

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-person office visit
Description: Post-operative visit to occur in-person with provider

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Teleheath visit
Description: Post-operative visit to occur via telehealth software platform with provider
Study: NCT04306744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vorso PROTECT System
Description: The Vorso PROTECT System is designed to deliver targeted, imperceptible, non-invasive stimulation to the ear to treat the signs and symptoms (e.g., tender and swollen joints, pain, synovitis) of patients with rheumatoid arthritis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vorso PROTECT System - Sham (OFF)
Description: Identical device to experimental arm, but the device will not deliver stimulation
Study: NCT02838719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural Dexamethasone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexamethasone acetate
Study: NCT00444041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: neoadjuvant therapy prior to elective surgery
Study: NCT04025775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX Closed-loop
Description: The CamAPS HX closed-loop system comprises~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~* Glooko/Diasend cloud upload system to monitor CGM/insulin data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Daily Insulin Injections (Control)
Description: Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
Study: NCT03692793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
Study: NCT00416130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
Study: NCT03962790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST
Description: etafilcon A contact lenses made with a new manufacturing technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST
Description: etafilcon A contact lenses made with a new manufacturing technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST
Description: etafilcon A contact lenses made with the current manufacturing technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST
Description: etafilcon A contact lenses made with the current manufacturing technology
Study: NCT00774553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
Study: NCT04535531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 10.3% berdazimer
Description: Topically once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Topically once daily
Study: NCT03579186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKS
Description: Optokinetic stimulation
Study: NCT02993952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
Study: NCT04424082

Intervention type: OTHER
Group type: OTHER
Intervention: Removal of dead space filter
Description: Dead space filters will be removed and Vcap parameters (VCO2 ml/min, PaCO2 kPa, alveolar dead space in ml) recorded before and after removal
Study: NCT00381043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate (Campral)
Description: The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acamprosate (Campral)
Description: The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
Study: NCT01028079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
Study: NCT03948087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Removable Rigid Dressing (VRRD)
Description: Intra-operative application of device.
Study: NCT02120664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB
Study: NCT02058290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine sulfate or Sponsor-approved equivalent
Description: Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study: NCT03923010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
Study: NCT02379065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Aerogen Aeroneb Solo©

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phillips Respironic© mask
Study: NCT01629056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: RF ablation
Description: RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
Study: NCT00315588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet Transplantation
Description: Islet Transplantation in subjects with a previous kidney transplant.
Study: NCT04121039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: POF
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT01761539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aggressive Hydration
Description: Receives 20cc/kg bolus and 3cc/kg/hr thereafter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Hydration
Description: Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
Study: NCT02581176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT00877071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC Bead loaded with doxorubicin
Description: LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
Study: NCT04022005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide, Rituximab, Gemcitabine,Oxaliplatin
Description: All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy.
Study: NCT00570427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Description: Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management
Description: If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
Study: NCT01057108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOSTRAP Chewing Gum
Description: 20 mg BID

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOSTRAP Chewing Gum
Description: 40 mg BID

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOSTRAP Chewing Gum
Description: 20 mg TID
Study: NCT00468754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pumps
Study: NCT01057108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOSTRAP Chewing Gum
Description: 20 mg TID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewing gum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewing gum
Study: NCT02737020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola
Description: Rhodiola rosea 200mg pill up to four times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to four times a day
Study: NCT04484766

Intervention type: OTHER
Intervention: Primary data collection
Description: Primary data collection takes place via questionnaires outside the study centre.~All other investigations take place at the study centre:~* Physical examination: height, weight, BMI, blood pressure~* Cardiac examination: cardiac output~* Vascular measurements: Carotid intima media thickness, total peripheral resistance, blood pressure, flow-mediated vascular dilatation, critical flicker frequency, pulse wave velocity, augmentation index~* Serum analysis: basic laboratory, multiplex analysis (human vascular inflammation, human angiogenesis and adhesion molecule panel)
Study: NCT01608087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695502
Description: BI 695502 single i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab single i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab single i.v. infusion
Study: NCT04201158

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Capacity
Description: Modified Shuttle Walk Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Capacity
Description: Modified Shuttle Walk Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Capacity
Description: Modified Shuttle Walk Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Capacity
Description: Modified Shuttle Walk Test
Study: NCT01895608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation + dual-tasking
Description: Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard balance rehabilitation
Description: Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training (speed of processing)
Description: Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training (general cognition)
Description: General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
Study: NCT04183140

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary percutaneous coronary intervention
Description: primary percutaneous coronary intervention via transulnar or transradial access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary percutaneous coronary intervention
Description: primary percutaneous coronary intervention via transulnar or transradial access
Study: NCT03134534

Intervention type: PROCEDURE
Group type: OTHER
Intervention: VATS lobectomy
Description: a minimal invasive surgical types for NSCLC: VATS lobectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RATS lobectomy
Description: a minimal invasive surgical types for NSCLC: RATS lobectomy
Study: NCT03879603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-WEVVLP073-00-VP
Description: VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-WEVVLP073-00-VP
Description: VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-WEVVLP073-00-VP
Description: VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-WEVVLP073-00-VP
Description: VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-WEVVLP073-00-VP
Description: VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-WEVVLP073-00-VP
Description: VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRC-GENMIX083-AL-VP
Description: VRC-GENMIX083-AL-VP is an adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRC-GENMIX083-AL-VP
Description: VRC-GENMIX083-AL-VP is an adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRC-GENMIX083-AL-VP
Description: VRC-GENMIX083-AL-VP is an adjuvant
Study: NCT04263298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg Days 0, 14, 28, then every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Oral Product
Description: Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
Study: NCT03158389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG101
Description: weekly i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: twice daily (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: orally on 5 days of a 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: i.v. every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: weekly i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: orally on 21 days of a 28 days cycle
Study: NCT01003600

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
Study: NCT03648671

Intervention type: DRUG
Intervention: safinamide metansolfonato (12 weeks)
Description: safinamide metansolfonato

Intervention type: DRUG
Intervention: safinamide metansolfonato (12 weeks)
Description: safinamide metansolfonato

Intervention type: DRUG
Intervention: rasagilina mesilato (12 weeks)
Description: rasagilina mesilato

Intervention type: DRUG
Intervention: rasagilina mesilato (12 weeks)
Description: rasagilina mesilato
Study: NCT04050124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promogran Prisma
Description: Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC) dressings
Description: standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC) dressings
Description: standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
Study: NCT00484562

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen delivery system
Description: Standard oxygen tank with pulse dose regulator
Study: NCT00544544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks